Is ISRG a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Intuitive Surgical (ISRG) rests on Razor-and-blade recurring revenue: Intuitive earns the majority of revenue from the single-use instruments, accessories, and service contracts consumed every time a da Vinci procedure runs, not just from selling systems. The bear case rests on iSRG trades at a premium valuation (about 49 times trailing earnings and 14 times sales as of October 2026), so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply; the stock's 24% decline in 2026 despite double-digit growth shows how that can play out. Analysts covering it publish targets from $324.00 to $685.00 against a $426.70 price, so even the professionals disagree by 75% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Intuitive Surgical (ISRG) is the dominant maker of robotic-assisted surgery systems, best known for the da Vinci platform used in minimally invasive procedures across urology, gynecology, general surgery, and other specialties. Its business model is razor-and-blade: Intuitive sells or places the large capital systems, then earns high-margin recurring revenue from the single-use instruments and accessories consumed in each procedure, plus service contracts. As the installed base of systems grows and procedure volumes rise, recurring revenue compounds. The company has expanded its platform with newer systems (including the da Vinci 5 and the Ion platform for lung biopsy), and benefits from surgeon training, hospital workflow integration, and a large library of validated procedures that create high switching costs. Intuitive went public in 2000 and is headquartered in Sunnyvale, California. The numbers have kept compounding. Revenue reached about $10.1 billion in fiscal 2025 (from $8.35 billion in 2024) and about $11.0 billion over the trailing twelve months, with net income of about $3.1 billion, a 28% profit margin and a 34% operating margin. Q2 2026 revenue of about $2.89 billion rose roughly 18.5% year over year, and EPS of $2.80 beat the $2.50 consensus, the fourth straight quarterly beat. The share price has moved the other way: at about $429 on October 16, 2026 ISRG is down about 24% year to date and about 1% over one year, after a 52-week range of $329 to $604, as investors weighed new competition from Medtronic and Johnson & Johnson against the premium multiple. The stock has rebounded about 23% over the past three months. Intuitive remains the clear leader in surgical robotics with a wide moat, a debt-free balance sheet with about $5.2 billion of cash, and a valuation that still prices in those qualities.
The bull case: what would have to be true for $685.00
The most optimistic published target on ISRG is $685.00, +60.5% from the $426.70 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Razor-and-blade recurring revenue.
Intuitive earns the majority of revenue from the single-use instruments, accessories, and service contracts consumed every time a da Vinci procedure runs, not just from selling systems. As the installed base and procedure volumes grow, this recurring stream compounds with high margins and far more predictability than one-time capital sales. Trailing revenue of about $11.0 billion and a gross margin near 67% show the model at scale.
2. Installed base and switching costs.
Hospitals invest heavily in da Vinci systems, surgeon training, and workflow integration, which creates strong switching costs and a durable relationship. A growing global installed base of systems expands the addressable procedure pool each year and gives Intuitive a platform to introduce new procedures and instruments. Procedure growth is the metric the market will scrutinize in the Q3 2026 report on October 20.
3. Platform expansion and new procedures.
Newer systems like da Vinci 5 and the Ion robotic bronchoscopy platform for lung biopsy extend Intuitive's reach into additional specialties. Each newly validated procedure type and geographic expansion broadens the runway for procedure growth, supported by clinical evidence and surgeon adoption. Analysts expect revenue of about $11.8 billion in 2026 and $13.3 billion in 2027, with EPS of about $10.80 and $12.11.
4. Earnings momentum ahead of Q3.
Intuitive has beaten consensus EPS in each of the last four reported quarters, most recently $2.80 versus $2.50 in Q2 2026. For Q3 2026 (reporting October 20) analysts expect EPS of about $2.64 on roughly $2.91 billion of revenue, about 10% earnings growth. A beat or miss on procedure volume and da Vinci 5 placements is likely to drive the near-term share price more than the headline EPS.
The bear case: what would have to be true for $324.00
The most pessimistic published target is $324.00, -24.1% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Intuitive Surgical is worth if the risks below bite instead of the drivers above.
ISRG trades at a premium valuation (about 49 times trailing earnings and 14 times sales as of October 2026), so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply; the stock's 24% decline in 2026 despite double-digit growth shows how that can play out. Competition is intensifying as Medtronic (Hugo), Johnson & Johnson and others bring rival surgical-robotics platforms to market, and October 2026 commentary has focused on new robotics competition. Hospital capital budgets are cyclical and can defer system purchases in tight economic periods. Reimbursement changes, regulatory scrutiny of new systems, and any safety or recall issues are risks. The company is also exposed to global healthcare-spending trends, tariffs and currency, and the high valuation leaves little room for execution missteps.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ISRG already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on ISRG
30 analysts cover ISRG, with an average target of $478.53 (+12.1% against $426.70) and a split of 26 buy, 7 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the ISRG forecast and price target page.
How is ISRG valued? (as of October 2026)
Snapshot for ISRG as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$11.0B
- Q2 2026 revenue growth: ~18.5% YoY
- Gross / operating margin: ~67% / ~34%
- Net income (TTM): ~$3.1B (EPS ~$8.72)
- P/E (trailing / forward): ~49x / ~35x
- Dividend: None
- Market cap: ~$152B
- Balance sheet: ~$5.2B cash, no debt
At about $429 on October 16, 2026, Intuitive trades near 49 times trailing earnings and 35 times forward earnings, cheaper than at the start of the year after a 24% share-price decline while earnings kept growing about 26%. The premium is still the central debate: bulls point to the durability of the razor-and-blade model and four straight earnings beats, while bears point to multiple-compression risk if procedure growth slows or Medtronic and J&J gain share. Q3 2026 results on October 20 carry a consensus of about $2.64 EPS on $2.91 billion of revenue.
How do you decide if ISRG is a buy?
Rather than asking whether ISRG is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ISRG indirectly through an index or sector ETF before adding more.
What would change your mind on ISRG
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Razor-and-blade recurring revenue stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: iSRG trades at a premium valuation (about 49 times trailing earnings and 14 times sales as of October 2026), so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply; the stock's 24% decline in 2026 despite double-digit growth shows how that can play out fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the ISRG stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ISRG against your real portfolio and see your actual exposure before deciding.
Investing in Intuitive Surgical with AI
Connect the broker you already use and ask Walnut's AI how ISRG fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is ISRG a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Razor-and-blade recurring revenue, with revenue (ttm) at ~$11.0B. The bear case rests on iSRG trades at a premium valuation (about 49 times trailing earnings and 14 times sales as of October 2026), so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply; the stock's 24% decline in 2026 despite double-digit growth shows how that can play out. Analysts covering it are spread from $324.00 to $685.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell ISRG?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. ISRG trades at a premium valuation (about 49 times trailing earnings and 14 times sales as of October 2026), so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply; the stock's 24% decline in 2026 despite double-digit growth shows how that can play out. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $324.00, -24.1% from the $426.70 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for ISRG?
+
Razor-and-blade recurring revenue. Intuitive earns the majority of revenue from the single-use instruments, accessories, and service contracts consumed every time a da Vinci procedure runs, not just from selling systems. The most optimistic analyst target on ISRG is $685.00, +60.5% from the $426.70 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for ISRG?
+
ISRG trades at a premium valuation (about 49 times trailing earnings and 14 times sales as of October 2026), so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply; the stock's 24% decline in 2026 despite double-digit growth shows how that can play out. Competition is intensifying as Medtronic (Hugo), Johnson & Johnson and others bring rival surgical-robotics platforms to market, and October 2026 commentary has focused on new robotics competition. Hospital capital budgets are cyclical and can defer system purchases in tight economic periods. Reimbursement changes, regulatory scrutiny of new systems, and any safety or recall issues are risks. The company is also exposed to global healthcare-spending trends, tariffs and currency, and the high valuation leaves little room for execution missteps. The most pessimistic published target is $324.00, -24.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Intuitive Surgical do?
+
Dominant surgical-robotics maker (da Vinci), with a razor-and-blade model where instrument and service revenue compounds with procedure volume.
What would have to change for ISRG to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Razor-and-blade recurring revenue) stalling in the reported numbers rather than in the narrative, the risk above (iSRG trades at a premium valuation (about 49 times trailing earnings and 14 times sales as of October 2026), so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply; the stock's 24% decline in 2026 despite double-digit growth shows how that can play out) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What is Intuitive Surgical's ticker symbol?
+
ISRG, listed on Nasdaq. The company is Intuitive Surgical, Inc., headquartered in Sunnyvale, California. It went public in 2000 and trades during US market hours at every major US brokerage.
What does Intuitive Surgical do?
+
Intuitive Surgical makes robotic-assisted surgery systems, most notably the da Vinci platform used for minimally invasive procedures in urology, gynecology, general surgery, and other specialties. It also makes the Ion platform for robotic lung biopsy. It earns most revenue from single-use instruments, accessories, and service, not just system sales.
Why is ISRG considered a high-quality stock?
+
Intuitive has a razor-and-blade model where recurring, high-margin revenue from instruments and service grows with procedure volume on a large installed base. High switching costs, a 34% operating margin, about $5.2 billion of cash with no debt, and consistent procedure growth give it a wide moat that investors value highly.
Walnut is informational, not investment advice, and gives no verdict on ISRG. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.
Guides that feature ISRG
ISRG is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.